Linaclotide

What is Linaclotide?

Linaclotide (brand name LINZESS in the US, CONSTELLA in Europe) is a 14-amino-acid synthetic peptide that acts as a selective agonist of the guanylate cyclase-C (GC-C) receptor on the luminal surface of intestinal epithelial cells. It was approved by the FDA on August 30, 2012 for two indications:

• Irritable bowel syndrome with constipation (IBS-C) in adults
• Chronic idiopathic constipation (CIC) in adults

In June 2023 the FDA expanded the indication to include functional constipation in pediatric patients ages 6-17. Linaclotide is one of the highest-revenue peptide drugs globally, with peak annual sales exceeding $1 billion.

Structure and Origin

Linaclotide's design is biomimetic of bacterial heat-stable enterotoxin STa (the toxin produced by enterotoxigenic E. coli that causes traveler's diarrhea). The native bacterial peptide STa is a 19-AA peptide with three disulfide bonds; linaclotide is a 14-AA truncated analogue that retains GC-C agonist activity but is engineered for better half-life and tolerability.

Sequence: CCEYCCNPACTGCY, with three intramolecular disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13).

Mechanism of Action

• Apical GC-C activation — linaclotide binds GC-C on the luminal surface of intestinal enterocytes (it does not enter circulation in measurable amounts)
• Intracellular cGMP elevation — GC-C activation increases intracellular cGMP
• CFTR activation — cGMP activates protein kinase G II, which phosphorylates and opens CFTR chloride channels
• Increased chloride and bicarbonate secretion — fluid follows the secreted electrolytes osmotically into the lumen
• Softened stool, accelerated transit, reduced visceral pain — the increased luminal fluid plus extracellular cGMP signaling on submucosal afferent nerves contribute to improved bowel function and reduced abdominal pain

A clinically important feature is that linaclotide is minimally absorbed systemically — plasma levels are below the limit of detection in most subjects after oral dosing. This pharmacology profile drives its safety advantage: most side effects are confined to the GI tract (primarily diarrhea), with no systemic exposure-driven adverse events.

Clinical Evidence

Phase 3 IBS-C (Am J Gastroenterol 2012):

• 800 patients with IBS-C, 12 weeks of linaclotide 290 µg vs placebo
• FDA-defined responder rate (≥30% improvement in abdominal pain AND ≥1 additional CSBM): 33.7% linaclotide vs 13.9% placebo (p<0.0001)

Phase 3 CIC (NEJM 2011):

• Two trials, ~1,200 patients with CIC, 12 weeks of linaclotide vs placebo
• Significant improvements in CSBM frequency, stool consistency, and abdominal pain

Approval History

• August 30, 2012 — FDA approval for IBS-C and CIC in adults
• November 2012 — EMA approval (Constella)
• June 2023 — FDA pediatric expansion (functional constipation, ages 6-17)

Place in Therapy

Linaclotide is a first- or second-line treatment for IBS-C and CIC, often after laxative trials have failed or when abdominal pain is a prominent feature. The 290 µg once-daily dose is standard for IBS-C and CIC; a 145 µg dose is also approved for CIC; the pediatric dose for ages 6-17 is 72 µg.

Distinction from Plecanatide

Plecanatide (Trulance) is a separate FDA-approved peptide GC-C agonist (approved 2017). The two are mechanistically equivalent but structurally distinct:

Plecanatide's pH-dependent binding may produce a slightly milder diarrhea profile, but head-to-head trials are limited.

Safety Profile

The most common and dose-limiting adverse event is diarrhea, occurring in ~16–20% of patients. The label carries a contraindication in pediatric patients <2 years (based on neonatal mouse data showing severe dehydration). In adolescents and adults, no systemic adverse events have been linked to linaclotide because of its lack of systemic absorption.